Cardiovascular risk management of different ethnic groups with type 2 diabetes in primary care in New Zealand

Diabetes Research and Clinical Practice

Volumn 79, Issue 3, 2008, Pages 468-473

  Elley, C Raina ^a   Kenealy, Tim ^a   Robinson, Elizabeth ^a   Bramley, Dale ^b   Selak, Vanessa ^a   Drury, Paul L ^c   Kerse, Ngaire ^a   Pearson, Janet ^a   Lay Yee, Roy ^a   Arroll, Bruce ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^c AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Diabetes; Drug therapy; Ethnicity; Primary care; Quality of care

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALBUMINURIA; ARTICLE; ASIAN; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; DEMOGRAPHY; DISEASE DURATION; ETHNIC GROUP; FEMALE; GLYCEMIC CONTROL; GROUPS BY AGE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INDIAN; INSULIN TREATMENT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAORI; MORBIDITY; NEW ZEALAND; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PACIFIC ISLANDER; PREVALENCE; PRIMARY MEDICAL CARE; RENAL PROTECTION; RISK MANAGEMENT; SEX RATIO; SMOKING; SOCIAL STATUS;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; OBESITY; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 39649110377     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.09.018     Document Type: Article

References (36)

1. Passa P. Diabetes trends in Europe. Diabetes Metab. Res. Rev. 18 Suppl. 3 (2002) S3-S8
2. Seidell J.C. Obesity, insulin resistance and diabetes-a worldwide epidemic. Br. J. Nutr. 83 Suppl. 1 (2000) S5-S8
3. Joshy G., and Simmons D. Epidemiology of diabetes in New Zealand: revisit to a changing landscape. NZ. Med. J. 119 (2006) 1-15
4. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., and Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA 286 (2001) 1195-1200
5. Simmons D., Harry T., and Gatland B. Prevalence of known diabetes in different ethnic groups in inner urban South Auckland. NZ. Med. J. 112 (1999) 316-319
6. Simmons D. The epidemiology of diabetes and its complications in New Zealand. Diabet. Med 13 (1996) 371-375
7. Ministry of Health, Modelling Diabetes: Forecasts to 2011. 2002 [cited 2005 accessed 02/08/06]; Available from: http://www.moh.govt.nz/moh.nsf/.
8. Oldroyd J., Banerjee M., Heald A., and Cruickshank K. Diabetes and ethnic minorities. Postgrad. Med. J. 81 (2005) 486-490
9. Venkataraman R., Nanda N.C., Baweja G., Parikh N., and Bhatia V. Prevalence of diabetes mellitus and related conditions in Asian Indians living in the United States. Am. J. Cardiol. 94 (2004) 977-980
10. McBean A.M., Li S., Gilbertson D.T., and Collins A.J. Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: Whites, Blacks, Hispanics, and Asians. Diabetes Care 27 (2004) 2317-2324
11. Gu K., Cowie C.C., and Harris M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21 (1998) 1138-1145
12. Jeffreys M., Wright C., t Mannetje A., Huang K., and Pearce N. Ethnic differences in cause specific mortality among hospitalised patients with diabetes: a linkage study in New Zealand. J. Epidemiol. Commun. Health 59 (2005) 961-966
13. Bramley D., Hebert P., Tuzzio L., and Chassin M. Disparities in indigenous health: a cross-country comparison between New Zealand and the United States. Am. J. Public Health 95 (2005) 844-850
14. Davis P., Lay-Yee R., Dyall L., Briant R., Sporle A., Brunt D., et al. Quality of hospital care for Maori patients in New Zealand: retrospective cross-sectional assessment. Lancet 367 (2006) 1920-1925
15. Boltri J.M., Okosun I.S., Davis-Smith M., and Vogel R.L. Hemoglobin A1c levels in diagnosed and undiagnosed black, Hispanic, and white persons with diabetes: results from NHANES 1999-2000. Ethn. Dis. 15 (2005) 562-567
16. Miller S.T., Schlundt D.G., Larson C., Reid R., Pichert J.W., Hargreaves M., et al. Exploring ethnic disparities in diabetes, diabetes care, and lifestyle behaviors: the Nashville REACH 2010 community baseline survey. Ethn. Dis. 14 (2004) S38-S45
17. Hippisley-Cox J., O'Hanlon S., and Coupland C. Association of deprivation, ethnicity, and sex with quality indicators for diabetes: population based survey of 53,000 patients in primary care. BMJ 329 (2004) 1267-1269
18. Anonymous: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ, 1998; 317:703-713.
19. Sever P., Poulter N., Dahlof B., Wedel H., Collins R., Beevers G., et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (2005) 1151-1157
20. Anonymous: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352:854-865.
21. Anonymous: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352:837-853.
22. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
23. Haider A., Oh P., and Peloso P.M. An evidence-based review of ACE inhibitors in incipient diabetic nephropathy. Can. J. Clin. Pharmacol. 7 (2000) 115-119
24. Anonymous: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet, 2000; 355:253-259.
25. Ravid M., Lang R., Rachmani R., and Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch. Intern. Med. 156 (1996) 286-289
26. Anderson K.M., Odell P.M., Wilson P.W., and Kannel W.B. Cardiovascular disease risk profiles. Am. Heart J. 121 (1991) 293-298
27. New, Zealand Guidelines Group. Assessment and management of cardiovascular risk. 2003 [cited 2006 August 2006]; Available from: http://www.nzgg.org.nz.
28. New, Zealand Guidelines Group. Management of Type 2 Diabetes. 2003 [cited 2006 August 2006]; Available from: http://www.nzgg.org.nz.
29. US Dept., of Health and Human Services. International Classification of Diseases, Ninth Revision, Clinical Modification (1988), Public Health Service, US Dept of Health and Human Services, Washington, DC
30. SAS Institute, Inc. SAS/STAT 9.1 (2004), SAS Institute Inc., Cary, NC
31. Rafter N., Connor J., Hall J., Jackson R., Martin I., Parag V., et al. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk. NZ. Med. J. 118 (2005) U1676
32. Khaw K.T., Wareham N., Luben R., Bingham S., Oakes S., Welch A., et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322 (2001) 15-18
33. Rosen A.B., Karter A.J., Liu J.Y., Selby J.V., and Schneider E.C. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J. Gen. Intern. Med. 19 (2004) 669-675
34. Ministry of Health, The Annual Report 2005/06 including the Health and Independence Report: Annual Report for the year ended 30 June 2006: Director-General of Health's Annual Report on the State of Public Health 2006: Wellington, New Zealand. p. 95.
35. Rodondi N., Peng T., Karter A.J., Bauer D.C., Vittinghoff E., Tang S., et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann. Intern. Med. 144 (2006) 475-484
36. Simmons D., Schaumkel J., Cecil A., Scott D.J., and Kenealy T. High impact of nephropathy on 5-year mortality rates among patients with Type 2 diabetes mellitus from a multi-ethnic population in New Zealand. Diabet. Med. 16 (1999) 926-931